| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 14.054 | 30.091 | 8.341 | 1.977 | 3.471 | 10.770 |
| Total Income - EUR | - | - | - | 0 | 14.054 | 30.092 | 8.341 | 1.977 | 3.471 | 10.770 |
| Total Expenses - EUR | - | - | - | 2.175 | 19.444 | 15.060 | 11.122 | 8.501 | 13.754 | 18.252 |
| Gross Profit/Loss - EUR | - | - | - | -2.175 | -5.390 | 15.032 | -2.780 | -6.524 | -10.283 | -7.483 |
| Net Profit/Loss - EUR | - | - | - | -2.175 | -5.599 | 14.227 | -3.030 | -6.584 | -10.317 | -7.483 |
| Employees | - | - | - | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Invictus Pharmaceutical S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 26 | 126 | 0 | 15.010 | 11.143 | 9.634 | 3.706 |
| Current Assets | - | - | - | 1.121 | 2.848 | 8.005 | 4.658 | 5.672 | 3.567 | 6.645 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 2.393 | 827 | 27 |
| Receivables | - | - | - | 1.119 | 2.574 | 3.816 | 2.683 | 2.007 | 2.653 | 4.082 |
| Cash | - | - | - | 2 | 274 | 4.189 | 1.975 | 1.272 | 87 | 2.536 |
| Shareholders Funds | - | - | - | -2.089 | -7.648 | 6.724 | 3.544 | -3.028 | -13.336 | -20.744 |
| Social Capital | - | - | - | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | - | - | - | 3.237 | 10.623 | 1.281 | 16.123 | 19.844 | 26.536 | 31.094 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Invictus Pharmaceutical S.r.l.